Navigation Links
Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting
Date:6/1/2009

New Product Names for Recently Introduced MicroRNA-based Diagnostics Also Unveiled

SAN DIEGO, June 1 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, presented an overview of its proprietary oncology diagnostic platform yesterday at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando.

In a presentation entitled "Profiling of Receptor Tyrosine Kinases (RTK) Activation in Circulating Tumor Cells (CTCs) in Metastatic Tumors Using Proximity Mediated Microarray Immunoassay," Prometheus demonstrated that its novel microarray platform can successfully detect the activation of key cancer pathways EGFR and HER2 in CTCs isolated from blood samples of patients with high specificity and sensitivity as high as a single cell. Testing of samples from frozen breast cancer tissues demonstrated concordance between reported HER2 status based on immunohistochemistry (IHC), a commonly used biopsy-based method, and the Prometheus diagnostic platform. Further, an analysis of CTCs from metastatic breast cancer patients showed that more than 50% of patients with HER2 negative primary tumors had CTCs with activated HER2 and approximately 30% of these patients had both activated and amplified HER2 over time. A copy of the presentation can be found on the Company's website at www.prometheuslabs.com.

"As our understanding of molecular targets and cancer pathways increases, so too does our need for sophisticated diagnostics," said Henry Pan, M.D., Ph.D., Chief Scientific and Medical Officer of Prometheus. "We believe the sensitivity and specificity of our proprietary diagnostics may help oncologists to optimize the choice of a growing number of targeted therapies for breast, lung, colorectal and other cancers. In addition, we believe the ability to isolate CTCs from whole blood and fine needle aspirates will be less invasive than current methods of biopsy and enable real-time, continuous monitoring of patients post-treatment."

Prometheus is currently implementing multiple studies in a clinical setting with an initial focus on metastatic breast cancer. The Company submitted an application for New York State approval in the first quarter of 2009 and anticipates the commercial launch of its first oncology diagnostic product thereafter upon completion of selected ongoing clinical studies.

New Product Names for MicroRNA-based Diagnostics

Prometheus also unveiled new product names at ASCO for three recently introduced microRNA-based diagnostics:

  • ProOnc TumorSource Dx (sold as miRview(TM) mets outside the U.S.), a test designed to accurately identify the primary tumor site in patients with metastatic cancer;
  • ProOnc Squamous Dx (sold as miRview(TM) squamous outside the U.S.), a test to differentiate squamous from non-squamous non-small cell lung cancer; and
  • ProOnc Mesothelioma Dx (sold as miRview(TM) meso outside the U.S.), a test to differentiate mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the lung and pleura.

The Company acquired exclusive U.S. rights to the three tests from Rosetta Genomics in April 2009.

About Prometheus

Prometheus Laboratories Inc. is a specialty pharmaceutical and diagnostic company committed to developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and intends to apply these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary, high-value diagnostic testing services. By integrating pharmaceutical products and diagnostic testing services, Prometheus believes it can address the full continuum of care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego.

ProOnc TumorSource Dx, ProOnc Squamous Dx and ProOnc Mesothelioma Dx are trademarks of Prometheus Laboratories Inc.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Is extra-corporal liver support with prometheus safe in patients with end-stage liver disease?
2. Updated GOLD report presents new understandings in diagnosis, treatment and prevention of COPD
3. The Art Of Maternity(TM) at Destination Maternity(R) Presents A Sacred Passage Into Motherhood; the Art of Belly Masking to Belly Casting
4. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
5. VNUS Medical Technologies Presents at William Blair Small-Cap Growth Stock Conference
6. NARSAD - Worlds Leading Mental Health Research Charity - Presents 19th Annual New York Mental Health Symposium, Oct. 19th & 20th
7. Retirement Living TV Presents Sex, Drugs and Rock N Roll
8. AviaraDx Presents at 2007 BIOCOM Investor Conference
9. NARSAD - the Worlds Leading Mental Health Research Charity - Presents 2007 Prizes for Outstanding Psychiatric Research at New York Gala, October 19th
10. California Science Center Science Matters Speakers Program Presents The Science and Ethics of Fear
11. Borgata Heart & Soul Foundation Presents Third Annual Women in Wine Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... ... announced a new Specialty Pharmacy Patient Satisfaction Award that will recognize specialty pharmacies ... quarterly results from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction Survey compiled throughout ...
(Date:5/2/2016)... ... May 02, 2016 , ... Visceral fat, also known as ... kidneys, liver and pancreas. If not properly addressed, visceral fat can lead to ... Medicine, Medical Oncology and Palliative Care, warns against the dangers of visceral fat. ...
(Date:5/2/2016)... (PRWEB) , ... May 02, ... ... researchers report that many commonly used prescription medications, including anxiolytics, painkillers, antidepressants ... mitigate these risks, Novus Medical Detox Center —a leading Florida-based drug ...
(Date:5/2/2016)... , ... May 02, 2016 , ... Pregnancy Awareness Month ... trying to conceive. , “If you are ready to have a baby, ... “My book, HealthChequesTM: Journal Babies is your Personal Conception & Pregnancy Organizer, written ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... and urgent care facilities designed to automate and improve the rapid diagnosis, triage ... it is demonstrating their platform, application, and mobile experience for the first time ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)...   Acsis , a leading provider of supply ... research and advisory firm IDC has named it a ... Pharmaceutical Track and Trace Software 2016 Vendor Assessment (doc ... of the capabilities and business strategies of 10 vendors ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/28/2016)... 2016 New market research ... a report that provides an overview of the ... by identifying new targets and MOAs to produce ... discussed in this H1 2016 Osteoarthritis Pipeline report ... Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, ...
(Date:4/27/2016)... 2016   ... sur le trimestre, soutenu par une croissance de ... Croissance de +16% des ventes aux hôpitaux et ... Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur de ... son chiffre d,affaires pour le premier trimestre clos ...
Breaking Medicine Technology: